Renal status in elderly patients with type 2 diabetes

Kazunaga Takamatsu

Received: 3 May 2018 / Accepted: 10 September 2019 / Published online: 23 September 2019 © The Author(s) 2019

Abstract

Background In Japan, there has been a remarkable increase in the incidence of type 2 diabetes in elderly patients. This study aimed to clarify the renal status in elderly patients with type 2 diabetes.

Participants and methods There were 978 patients with type 2 diabetes who were classified into three groups: Group 1 (aged < 65 years of age), Group 2 (65–74 years of age), and Group 3 (≥ 75 years of age). Estimated glomerular filtration rate (eGFR) and urinary albumin level were measured. Moreover, the frequencies of each stage of chronic kidney disease for each group were determined, and differences among the three groups were analyzed.

Results The mean eGFR in Group 3 was 63.2 ± 19.1 mL/min/1.73 m², which was lower than those in Group 1 (83.3 ± 22.8 mL/min/1.73 m²) and Group 2 (72.0 ± 19.4 mL/min/1.73 m²). The percentage of low eGFR (< 60 mL/min/1.73 m²) with normo- and microalbuminuria in Group 3 was 31.9%, which was higher than the percentages observed in Group 1 (7.1%) or Group 2 (16.1%). Diabetic macroangiopathy was frequently observed in these patients. The frequency of low eGFR with proteinuria was 10.2%. In this group, diabetic micro- and macroangiopathies were frequently noted.

Conclusion In elderly patients with type 2 diabetes, renal dysfunction is characterized by low eGFR with normo- and microalbuminuria. In this group, macroangiopathy was more common than microangiopathy. The elderly patients with diabetes with low eGFR with proteinuria frequently had micro- and macroangiopathies.

Keywords Renal disorder · Elderly patients · Type 2 diabetes · Chronic kidney disease

Introduction

According to the National Health and Nutrition Survey, the incidence of diabetes increases with age [1]. As the number of elderly patients with diabetes increases, there are increasing needs to understand the characteristics of abnormal glucose metabolism and diabetic complications including nephropathy in these patients. With regard to renal damage in elderly patients with diabetes, the high incidence of chronic kidney disease (CKD) (reduced renal function), microalbuminuria and macroangiopathy including coronary heart disease (CHD), and rapid decline in renal function have been reported [2–7].

The Japanese Society of Nephrology has established a system for staging CKD. These stages are classified as A1 (< 30 mg/g Cr), A2 (30–299 mg/g Cr), and A3 (≥ 300 mg/g Cr) based on urinary albumin concentration (U-Alb) and G1 (≥ 90 mL/min/1.73 m²), G2 (60–89 mL/min/1.73 m²), G3a (45–59 mL/min/1.73 m²), G3b (30–44 mL/min/1.73 m²), G4 (15–29 mL/min/1.73 m²), and G5 (< 15 mL/min/1.73 m²) based on the estimated glomerular filtration rate (eGFR). The risks of death, end-stage renal failure, and cardiovascular mortality at each stage are indicated [8]. However, the previous studies did not evaluate the characteristics of patients divided into CKD stages [2–7].

In this study, to clarify the renal status in elderly patients with type 2 diabetes, participants were divided into three groups based on age, and the frequencies of each stage in each group were determined and compared with clinical profiles.
level ≥ 200 mg/dL or plasma glucose level in 2 h of 75 g glucose tolerance test ≥ 200 mg/dL, and criterion 2, hemoglobin A1c level ≥ 6.5%. The diagnosis of diabetes mellitus was made by meeting two or more items in criterion 1 on different days or criteria 1 and 2 on the same day. The stage for each patient was determined based on the eGFR, U-Alb, and urine protein levels, and then the frequencies for each stage of CKD in each group were obtained. To characterize renal disorders among individuals aged ≥ 75 years, patients' clinical profiles were examined and compared. Regarding patients' clinical background, retinopathy was diagnosed by ophthalmologists. Hypertension was defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg and/or undergoing hypertensive treatment. Dyslipidemia was defined as low-density lipoprotein cholesterol level ≥ 140 mg/dL and/or triglyceride level ≥ 220 mg/dL and/or high-density lipoprotein cholesterol level < 40 mg/dL and/or undergoing treatment for dyslipidemia. The presence or absence of CHD, cerebrovascular disease (CVD) and peripheral artery disease (PAD) was confirmed by referring to each patient's individual medical record. Patients with history of percutaneous coronary interventions or coronary artery bypass grafting were diagnosed as having CHD. CVD was diagnosed by specialists according to the significant findings of brain magnetic resonance imaging or computed tomography. PAD was diagnosed by specialists according to clinical symptoms and the significant findings of angiography or multi-detector computed tomography findings.

eGFR as per the modification of diet in Renal Disease study equation using the Japanese coefficient was calculated [10]. Serum creatinine, U-Alb, and urinary protein levels were measured using the enzymatic, immunoturbidimetric, and pyrogallol red methods, in the BML, a commercial laboratory facility. This study was a cross-sectional study.

Results

Clinical profiles of patients are shown in Table 1. There were 978 patients with type 2 diabetes (male/female ratio, 618/360; mean age, 66.7 ± 10.8 years) who were under treatment in the clinic from January 4, 2016 until December 30, 2016. This was a cross-sectional study.

Participants were divided into three groups: Group 1 (< 65 years) included 366 patients (male/female ratio, 265/101; mean age, 55.7 ± 7.8 years), Group 2 (65–74 years) included 386 patients (male/female ratio, 239/147; mean age, 69.2 ± 2.9 years), and Group 3 (≥ 75 years) included 226 patients (male/female ratio, 114/112; mean age, 80.2 ± 4.2 years).

eGFR (Table 1)

Data distributions were examined using the χ² test and histograms. For each group, eGFR was normally distributed (Group 1, p = 0.2092; Group 2, p = 0.3335; Group 3, p = 0.5091).

The mean eGFR in Group 3 was 63.2 ± 19.1 mL/min/1.73 m², which was significantly lower than those observed in Group 1 (83.3 ± 22.8 mL/min/1.73 m²) and Group 2 (72.0 ± 19.4 mL/min/1.73 m²) (p < 0.0001 vs. Group 1 and Group 2). The mean eGFR in Group 2 was significantly lower than that in Group 1 (p < 0.0001).

In men, the mean eGFR in Group 3 was 64.4 ± 18.2 mL/min/1.73 m², which was significantly lower than those observed for Group 1 (83.4 ± 22.2 mL/min/1.73 m²) and Group 2 (73.7 ± 20.2 mL/min/1.73 m²) (p < 0.0001 vs. Group 1 and Group 2).

In women, the mean eGFR in Group 3 was 60.5 ± 18.2 mL/min/1.73 m², which was significantly lower than those observed in Group 1 (89.5 ± 22.9 mL/min/1.73 m²) and Group 2 (73.8 ± 19.7 mL/min/1.73 m²) (p < 0.0001 vs. Group 1 and Group 2).

G classification (Table 2, Fig. 1)

The number of cases at each stage of CKD severity classification in each group is shown in Table 2. The frequencies of G classification in each group are shown in Fig. 1. The frequency of G1 in Group 3 was 6.6%, which was significantly lower than the Group 1 frequency of 34.4% and the Group 2 frequency of 16.8% (p < 0.0001 vs. Group 1 and Group 2). The Group 2 frequency was significantly lower than that of Group 1 (p < 0.0001).

The frequency of G2 in Group 3 was 51.3%, which was significantly lower than the Group 2 frequency of 58.5% (p = 0.0045). There was no statistically significant difference in the frequency of G2 between Group 3 and Group 1.

The frequency of G3a in Group 3 was 25.2%, which was significantly higher than those in Group 1 (6.8%) and Group 2 (16.3%) (p < 0.0001 vs. Group 1 and p = 0.0001 vs. Group 2). The frequency of G3a in Group 2 was significantly higher than that observed in Group 1 (p < 0.0001).

The frequency of G3b in Group 3 was 12.8%, which was significantly higher than those in Group 1 (3.8%) and Group 2 (6.5%) (p < 0.0001 vs. Group 1 and p = 0.0002 vs. Group 2). The frequency of G3b in Group 2 was significantly higher than that in Group 1 (p = 0.0393).

The frequency of G4 in Group 3 was 4.0%, which was significantly higher than that observed in Group 1 (1.4%)
Table 1 Clinical profiles of the patients

|                               | Group 1          | Group 2          | Group 3          |
|--------------------------------|------------------|------------------|------------------|
| Cases                         | 366              | 386              | 226              |
| Age (years)                   | 55.7 ± 7.8       | 69.2 ± 2.9<sup>a</sup> | 80.2 ± 4.2<sup>b</sup> |
| Male/female ratio             | 265/101          | 239/147<sup>a</sup> | 114/112<sup>b</sup> |
| Disease duration (years)      | 10.1 ± 8.9       | 11.2 ± 5.3<sup>c</sup> | 15.4 ± 7.6<sup>b</sup> |
| BMI (kg/m²)                   | 25.7 ± 4.3       | 24.1 ± 3.6<sup>a</sup> | 23.6 ± 3.3<sup>a</sup> |
| eGFR (mL/min/1.73 m²)         | 83.3 ± 22.8      | 72.0 ± 19.4<sup>a</sup> | 63.2 ± 19.1<sup>b</sup> |
| Urinary albumin (mg/g Cr)     | 74.0 ± 330.3<sup>d</sup> | 60.0 ± 178.4<sup>e</sup> | 114.9 ± 348.4<sup>f,g</sup> |
| Urinary protein (mg/g Cr)     | 2815.9 ± 3124.7<sup>b</sup> | 2207.0 ± 2715.4<sup>f</sup> | 3888.5 ± 4803.8<sup>i</sup> |
| CPG (mg/dL)                   | 180.6 ± 87.1     | 167.3 ± 60.5<sup>a</sup> | 170.7 ± 59.1     |
| HbA1C (%)                     | 7.3 ± 1.4        | 7.0 ± 1.0<sup>f</sup> | 7.0 ± 1.0<sup>bm</sup> |
| Hb (g/dL)                     | 14.3 ± 1.5       | 13.7 ± 1.4<sup>a</sup> | 13.0 ± 1.4<sup>b</sup> |
| RBC (×10⁴)                    | 467.1 ± 47.7     | 447.4 ± 42.1<sup>a</sup> | 424.2 ± 46.6<sup>b</sup> |
| T-Ch (mg/dL)                  | 193.0 ± 34.1     | 184.3 ± 29.5<sup>a</sup> | 180.7 ± 29.2<sup>b</sup> |
| TG (mg/dL)                    | 185.6 ± 138.6    | 141.7 ± 81.9<sup>a</sup> | 126.1 ± 81.9<sup>an</sup> |
| HDL-C (mg/dL)                 | 51.9 ± 15.1      | 53.6 ± 14.5      | 53.4 ± 15.7      |
| LDL-C (mg/dL)                 | 104.0 ± 33.1     | 102.3 ± 26.2     | 101.8 ± 27.0     |
| Uric acid (mg/dL)             | 5.3 ± 1.3        | 5.1 ± 1.3<sup>p</sup> | 5.2 ± 1.3        |
| sBP (mmHg)                    | 128.6 ± 13.8     | 130.7 ± 11.3<sup>p</sup> | 129.6 ± 9.8      |
| dBP (mmHg)                    | 76.0 ± 7.6       | 74.5 ± 5.9<sup>g</sup> | 72.7 ± 5.3<sup>b</sup> |
| Retinopathy (yes/no)          | 51/315           | 114/272<sup>a</sup> | 74/152<sup>b</sup> |
| Hypertension (yes/no)         | 199/167          | 241/145<sup>a</sup> | 147/79<sup>a</sup> |
| ARB/ACE-I (yes/no)            | 144/222          | 164/222          | 97/129           |
| CCB (yes/no)                  | 107/259          | 148/238<sup>a</sup> | 106/120<sup>as</sup> |
| Dyslipidemia (yes/no)         | 204/162          | 198/188          | 122/104          |
| Statin (yes/no)               | 112/254          | 157/229<sup>a</sup> | 113/113<sup>as</sup> |
| Fibrate (yes/no)              | 46/320           | 10/376<sup>e</sup> | 6/220<sup>e</sup> |
| CHD (yes/no)                  | 18/348           | 35/351<sup>a</sup> | 47/179<sup>b</sup> |
| CVD (yes/no)                  | 30/336           | 39/347           | 32/194<sup>v</sup> |
| PAD (yes/no)                  | 9/357            | 7/379            | 17/209<sup>ws,x</sup> |
| Therapy (D/O/I)               | 70/274/22        | 59/285/42<sup>a</sup> | 38/165/23<sup>a</sup> |

BMI body mass index, eGFR estimated glomerular filtration rate, CPG casual plasma glucose, HbA1c hemoglobin A1c, Hb hemoglobin, RBC red blood cell, T-Ch total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, sBP systolic blood pressure, dBP diastolic blood pressure, ARB angiotensin II receptor blocker, ACE-I angiotensin-converting enzyme inhibitor, CCB calcium channel blocker, CHD coronary heart disease, CVD cerebrovascular disease, PAD peripheral artery disease, Therapy (D/O/I) therapy (diet/oral agents/insulin)

<sup>a</sup>p < 0.0001 vs. Group 1
<sup>b</sup>p < 0.0001 vs. Group 1 and Group 2
<sup>c</sup>p = 0.0382 vs. Group 1
<sup>d</sup>n = 346
<sup>e</sup>n = 353
<sup>f</sup>n = 213
<sup>g</sup>p = 0.0322 vs. Group 2
<sup>h</sup>n = 20
<sup>i</sup>n = 33
<sup>j</sup>n = 13
<sup>k</sup>p = 0.0157 vs. Group 1
<sup>l</sup>p = 0.0026 vs. Group 1
<sup>m</sup>p = 0.0090 vs. Group 1
<sup>n</sup>p = 0.0153 vs. Group 2
<sup:o</sup>p = 0.0199 vs. Group 1
<sup>p</sup>p = 0.0208 vs. Group 1
The frequency of G3a + G3b + G4, corresponding to CKD, in Group 3 was 42.0%, which was significantly higher than the frequencies observed in Group 1 (12.0%) and Group 2 (24.6%) (\( p < 0.0001 \text{ vs. Group 1 and Group 2} \)).

In men, the frequency of G3a + G3b + G4 in Group 3 was 38.6%, which was significantly higher than those in Group 1 (14.0%) and Group 2 (12.8%) (\( p < 0.0001 \text{ vs. Group 1 and Group 2} \)). In women, the frequency of G3a + G3b + G4 in Group 3 was 45.5%, which was significantly higher than those in Group 1 (9.6%) and Group 2 (12.4%) (\( p < 0.0001 \text{ vs. Group 1 and Group 2} \)).

A classification (Table 2, Fig. 2)

The frequencies of A classification in each group are shown in Fig. 2. The frequency of A1 in Group 3 was 51.8%, which was significantly lower than the frequency observed for Group 1 (67.2%) or Group 2 (65.0%) (\( p < 0.0001 \text{ vs. Group 1 and Group 2} \)).

The frequency of A2 in Group 3 was 34.5%, which was significantly higher than those observed in Group 1 (16.8%) and Group 2 (22.5%) (\( p < 0.0001 \text{ vs. Group 1 and Group 2} \)).

The frequency of A3 in Group 3 was 13.7%, which was significantly higher than that observed in Group 1 (9.6%) (\( p = 0.0209 \)).

![Fig. 1 G classification frequencies by group. *\( p < 0.0001 \text{ vs. Group 1} \), **\( p < 0.0001 \text{ vs. Group 1 and Group 2} \), ***\( p = 0.0045 \text{ vs. Group 1 and p = 0.0001 vs. Group 2} \), ****\( p < 0.0001 \text{ vs. Group 1 and p = 0.0001 vs. Group 2} \)]

![Fig. 2 A classification frequencies by group. *\( p < 0.0001 \text{ vs. Group 1} \) and vs. Group 2 \)]
Clinical and Experimental Nephrology (2020) 24:53–62

The frequency of A1 and G3a + G3b + G4, corresponding to CKD, in Group 3 was 17.2%, which was significantly higher than those observed in Group 1 (4.4%) and Group 2 (9.6%) (p < 0.0001 vs. Group 1 and p = 0.0001 vs. Group 2).

The frequency of A2 and G3a + G3b + G4 in Group 3 was 14.6%, which was significantly higher than those observed in Group 1 (2.7%) and Group 2 (6.5%) (p < 0.0001 vs. Group 1 and Group 2).

The frequency of A1 + A2 and G3a + G3b + G4 in Group 3 was 31.9% (72 cases), which was significantly higher than those observed in Group 1 (7.1%) and Group 2 (16.1%) (p < 0.0001 vs. Group 1 and Group 2).

The frequency of A1 and G3a + G3b + G4 in Group 3 was 10.2% (23 cases), which was significantly higher than those in Group 1 (4.9%) (p < 0.0001 vs. Group 1) and was not significantly different with that in Group 2 (8.5%).

Clinical profiles of G3a + G3b + G4 in Group 3 (Tables 3, 4, and 5)

In comparing the clinical profiles of Group 1 (34 cases) and A2 (39 cases) in G3a + G3b + G4 of Group 3, women exhibited relative high frequencies (male/female ratio, 19/14 vs. 14/25, p = 0.0023), and PAD was less frequent (2/31 vs. 6/33, p = 0.0147) in A2. However, there were no differences between two groups in the mean age, disease duration, HbA1c level, and the frequencies of retinopathy, CHD, CVD and macroangiopathy (80.4 ± 3.8 vs. 80.7 ± 4.9 years old, 14.7 ± 6.2 vs. 15.5 ± 8.1 years, 7.0 ± 0.8 vs. 6.8 ± 0.8%, 17.9 vs. 21.2%, 28.2 vs. 36.3%, 25.6% vs. 18.2%, 69.2 vs. 60.6%). Therefore, A1 and A2 clinical profiles were grouped for comparison with other groups.

In patients with A1 + A2 and G3a + G3b + G4, clinical profiles of each group were compared (Table 3). There were significantly more women in Group 3 than Group 1 (male/female ratio, 34/38 vs. 22/4, p < 0.0001). The average disease duration in Group 3 was significantly longer than those observed in Groups 1 and 2 (15.2 ± 7.1 years vs. 10.4 ± 4.8 years, p = 0.0001, vs. 12.7 ± 6.0 years, p = 0.0330). The frequency of retinopathy in Group 3 was significantly lower than that in Group 2 (19.4% vs. 33.9%, p = 0.0041). The frequency of CHD in Group 3 was significantly higher than those in Groups 1 and 2 (31.9% vs. 11.5%, p = 0.0256, vs. 9.7%, p < 0.0001). The frequencies of CVD and PAD in Group 3 were significantly higher than those in Group 1 (22.2% vs. 7.7%, p < 0.001, 11.1% vs. 3.8%, p = 0.0482). The frequency of CHD, CVD, and PAD as manifestations of macroangiopathy was significantly higher in Group 3 compared to those in Groups 1 and 2 (65.3% vs. 23.1%, p < 0.0001, vs. 27.4%, p < 0.0001).

Table 3 Clinical profiles of patients with A1 + A2 and G3a + G3b + G4 in each group

| Cases | Group 1 | Group 2 | Group 3 |
|-------|---------|---------|---------|
| Age (years) | 59.7 ± 5.5 | 70.1 ± 2.8 | 80.6 ± 4.4 |
| Male/female ratio | 22/4 | 34/28 | 34/38 |
| Disease duration (years) | 10.4 ± 4.8 | 12.7 ± 6.0 | 15.2 ± 7.1 |
| BMI (kg/m²) | 25.8 ± 2.9 | 24.6 ± 3.2 | 23.5 ± 2.8 |
| eGFR (mL/min/1.73 m²) | 49.9 ± 8.6 | 49.4 ± 7.6 | 47.1 ± 9.0 |
| Urinary albumin (mg/g Cr) | 34.8 ± 39.3 | 50.5 ± 66.1 | 52.7 ± 69.4 |
| CPG (mg/dL) | 164.7 ± 63.0 | 161.3 ± 51.0 | 172.5 ± 55.3 |
| HbA1C (%) | 7.1 ± 1.2 | 6.8 ± 0.7 | 6.9 ± 0.8 |
| Hb (g/dL) | 13.8 ± 1.3 | 13.5 ± 1.4 | 12.6 ± 1.3 |
| RBC (×10⁴) | 428.0 ± 73.3 | 441.4 ± 45.1 | 413.2 ± 43.1 |
| T-Ch (mg/dL) | 188.3 ± 28.7 | 179.8 ± 25.4 | 174.9 ± 28.5 |
| TG (mg/dL) | 180.6 ± 75.6 | 153.1 ± 90.2 | 134.7 ± 61.9 |
| HDL-C (mg/dL) | 48.2 ± 14.9 | 50.1 ± 14.7 | 50.6 ± 15.8 |
| LDL-C (mg/dL) | 104.0 ± 23.5 | 99.2 ± 23.9 | 97.4 ± 25.1 |
| Uric acid (mg/dL) | 6.2 ± 1.4 | 6.0 ± 1.3 | 5.9 ± 1.2 |
| sBP (mmHg) | 124.8 ± 14.3 | 129.4 ± 11.5 | 128.7 ± 9.4 |
| dBP (mmHg) | 73.8 ± 7.8 | 73.5 ± 6.0 | 72.1 ± 5.7 |
| Retinopathy (yes/no) | 3/23 | 21/41 | 4/58 |
| Hypertension (yes/no) | 15/11 | 41/21 | 20/20 |
| ARB/ACE-I (yes/no) | 11/15 | 31/31 | 31/41 |
| CCB (yes/no) | 7/19 | 23/39 | 40/32 |
| Dyslipidemia (yes/no) | 16/10 | 35/27 | 34/38 |
| Statin (yes/no) | 9/17 | 29/33 | 34/38 |
| Fibrate (yes/no) | 6/20 | 2/30 | 8/68 |
| CHD (yes/no) | 3/23 | 6/56 | 23/49 |
| CVD (yes/no) | 2/24 | 9/53 | 16/54 |
| PAD (yes/no) | 1/25 | 2/60 | 8/64 |
| Therapy (D/O/I) | 5/18/3 | 9/42/11 | 11/55/6 |

BMI body mass index, eGFR estimated glomerular filtration rate, CPG casual plasma glucose, HbA1c hemoglobin A1c, Hb hemoglobin, RBC red blood cell, T-Ch total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, sBP systolic blood pressure, dBP diastolic blood pressure, ARB angiotensin II receptor blocker, ACE-I angiotensin-converting-enzyme inhibitor, CCB calcium channel blocker, CHD coronary heart disease, CVD cerebrovascular disease, PAD peripheral artery disease, Therapy (D/O/I) therapy (diet/oral agents/insulin)

a p < 0.0001 vs. Group 1
b p < 0.0001 vs. Group 1 and Group 2
c p = 0.0023 vs. Group 1
d p = 0.0330 vs. Group 2
e p = 0.0466 vs. Group 2
f p < 0.0001 vs. Group 2
g p = 0.0101 vs. Group 1
h p = 0.0161 vs. Group 1
i p = 0.0041 vs. Group 2
j p = 0.0033 vs. Group 1
k p = 0.0034 vs. Group 2
l p = 0.0256 vs. Group 1
m p = 0.0482 vs. Group 2
n p = 0.0271 vs. Group 2
Table 4  Clinical profiles of patients with A3 and G3a + G3b + G4 in each group

|                  | Group 1                  | Group 2                  | Group 3                  |
|------------------|--------------------------|--------------------------|--------------------------|
| Cases            | 18                       | 33                       | 23                       |
| Age (years)      | 55.0 ± 7.4               | 69.6 ± 2.7\(^a\)         | 81.8 ± 4.8\(^b\)         |
| Male/female ratio| 16/2                     | 25/8                     | 11/12\(^c\)             |
| Disease duration (years) | 14.9 ± 5.9               | 12.8 ± 5.7\(^d\)       | 22.0 ± 8.4\(\times\)^e |
| BMI (kg/m\(^2\)) | 27.6 ± 4.6               | 25.7 ± 4.6               | 23.5 ± 3.5\(^f\)         |
| eGFR (mL/min/1.73 m\(^2\)) | 37.3 ± 11.9               | 42.1 ± 13.8               | 37.7 ± 12.8          |
| Urinary albumin (mg/g Cr) | 1776.0 ± 1793.6\(\times\)^b | 465.5 ± 162.0\(\times\)^f | 705.9 ± 480.2\(\times\)^i |
| Urine protein (mg/g Cr) | 3494.8 ± 3513.0\(\times\)^d | 2479.2 ± 2964.7\(\times\)^j | 3724.1 ± 5031.0\(\times\)^k |
| CPG (mg/dL)      | 194.7 ± 97.9             | 175.3 ± 55.6             | 174.7 ± 52.7            |
| HbA1C (%)        | 7.6 ± 1.5                | 7.3 ± 0.8                | 7.2 ± 1.0               |
| Hb (g/dL)        | 13.3 ± 2.1               | 12.8 ± 1.5               | 12.3 ± 1.7              |
| RBC\(\times\)10\(^{12}\) | 433.1 ± 72.5             | 417.8 ± 48.4             | 398.5 ± 59.1            |
| T-Ch (mg/dL)     | 175.6 ± 29.0             | 173.5 ± 28.5             | 175.8 ± 27.7            |
| HDL-C (mg/dL)    | 49.1 ± 14.8              | 52.2 ± 18.9              | 46.5 ± 16.6             |
| LDL-C (mg/dL)    | 104.3 ± 44.5             | 105.1 ± 26.4             | 99.0 ± 22.6             |
| Uric acid (mg/dL)| 6.3 ± 1.3                | 5.8 ± 1.4                | 6.0 ± 1.1               |
| sBP (mmHg)       | 143.0 ± 17.7             | 134.8 ± 10.9             | 132.2 ± 12.5\(\times\) |
| dBP (mmHg)       | 83.1 ± 6.9               | 74.5 ± 5.5\(\times\)    | 72.4 ± 6.0\(\times\)    |
| Retinopathy (yes/no) | 18/0                     | 28/5                     | 20/3                     |
| Hypertension (yes/no) | 17/1                     | 33/0                     | 20/3\(\times\)          |
| ARB/ACE-I (yes/no) | 14/4                     | 29/4                     | 15/8\(\times\)          |
| CCB (yes/no)     | 13/5                     | 24/9                     | 16/7                     |
| Dyslipidemia (yes/no) | 9/9                     | 20/13                    | 15/8                     |
| Statin (yes/no)  | 6/12                     | 17/16                    | 15/8\(\times\)          |
| Fibrate (yes/no) | 1/17                     | 2/31                     | 0/23                     |
| CHD (yes/no)     | 3/15                     | 10/23                    | 9/14                     |
| CVD (yes/no)     | 3/15                     | 6/27                     | 6/17                     |
| PAD (yes/no)     | 4/14                     | 4/29                     | 2/21\(\times\)          |
| Therapy (D/O/I)  | 2/8/8                    | 1/18/14                  | 3/11/9                   |

BMI body mass index, eGFR estimated glomerular filtration rate, CPG casual plasma glucose, HbA1c hemoglobin A1c, Hb hemoglobin, RBC red blood cell, T-Ch total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, sBP systolic blood pressure, dBP diastolic blood pressure, ARB angiotensin II receptor blocker, ACE-I angiotensin-converting-enzyme inhibitor, CCB calcium channel blocker, CHD coronary heart disease, CVD cerebrovascular disease, PAD peripheral artery disease, Therapy (D/O/I) therapy (diet/oral agents/insulin)

\(^a\)p < 0.0001 vs. Group 1

\(^b\)p < 0.0001 vs. Group 1 and Group 2

\(^c\)p = 0.0013 vs. Group 2

\(^d\)p = 0.0035 vs. Group 1

\(^e\)p < 0.0001 vs. Group 2

\(^f\)p = 0.0036 vs. Group 1

\(^g\)p = 0.0498 vs. Group 2

\(^h\)n = 5

\(^i\)n = 7

\(^j\)n = 13

\(^k\)n = 13

\(^l\)n = 26

\(^m\)n = 10

\(^n\)p = 0.00426 vs. Group 1

\(^o\)p = 0.0373 vs. Group 1

\(^p\)p = 0.0261 vs. Group 2

\(^q\)p = 0.0063 vs. Group 2

\(^r\)p = 0.0045 vs. Group 1

\(^s\)p = 0.0417 vs. Group 1
In patients with A3 and G3a + G3b + G4, the clinical profiles of each group were compared (Table 4). There were significantly more women in Group 3 than in Groups 1 and 2 (male/female ratio, 11/12 vs. 16/2, \( p < 0.0001 \), vs. 25/8, \( p = 0.0013 \)). The disease duration in Group 3 was significantly longer than those observed in Groups 1 and 2 (22.0 ± 8.4 vs. 14.9 ± 5.9 years, \( p = 0.0035 \), vs. 12.8 ± 5.7 years, \( p = 0.0013 \)). There was no difference in the frequency of retinopathy among the three groups. The frequency of hypertension in Group 3 was significantly lower than that in Group 2 (87.0% vs. 100%, \( p = 0.0261 \)). There were no differences in the frequencies of dyslipidemia, CHD, and CVD among the three groups. The frequency of PAD in Group 3 was significantly lower than that in Group 1 (8.7% vs. 22.2%, \( p = 0.0417 \)). There was no difference in the frequency of macroangiopathy in the three groups.

In patients with G3a + G3b + G4, the clinical profiles were compared between those with A1 + A2 and A3 (Table 5). Systolic blood pressure was lower in A1 + A2 than in A3 in Group 1 (124.8 ± 14.3 vs. 143.0 ± 17.7 mmHg, \( p < 0.0001 \)) and Group 2 (129.4 ± 11.5 vs. 134.8 ± 10.9 mmHg, \( p = 0.0130 \)). There was no difference in systolic blood pressure in A1 + A2 and A3 in Group 3. In the frequency of retinopathy and hypertension, A1 + A2 was less frequent than A3 in all groups (11.5% vs. 100%, 33.9% vs. 84.8%, 19.4% vs. 87.0%, all \( p < 0.0001 \), 57.6% vs. 94.4%, 66.1% vs. 100%, 72.2% vs. 87.0%, all \( p < 0.0001 \)). The frequency of CHD was lower in A1 + A2 than in A3 in Group 2 (9.7% vs. 30.3%, \( p < 0.0001 \), and the frequency of PAD was lower in A1 + A2 than in A3 in Groups 1 and 2 (3.8% vs. 22.2%, \( p = 0.0242 \), 3.2% vs. 12.1%, \( p = 0.0319 \)). The frequency of macroangiopathy was lower in A1 + A2 than in A3 in Groups 1 and 2 (23.1% vs. 55.6%, 27.4% vs. 60.6%, both \( p < 0.0001 \)), but no difference was observed in Group 3. In the frequency of insulin treatment, A1 + A2 was less frequent than A3 in all groups (11.5% vs. 44.4%, \( p = 0.0155 \), 17.7% vs. 42.4%, \( p < 0.0001 \), 8.3% vs. 39.1%, \( p < 0.0001 \)).

### Discussion

The data obtained represent “real-world” findings from elderly patients aged ≥ 75 years with type 2 diabetes from one clinic in a local city in Japan.

Conventionally, in elderly patients with diabetes, it has been reported that the frequencies of decreased renal function and microalbuminuria are high [2, 4–7], but there are few studies on patients aged ≥ 75 years [6, 7]. In this study, the mean eGFR in patients aged ≥ 75 years decreased sequentially from Group 1 to Group 3. Correspondingly, Group 3 exhibited more frequent G3a, G3b, and G4 classifications than the other two groups. The frequency of eGFR < 60 mL/min/1.73 m² (G3a + G3b + G4) in Group 3 was 42.0%, which was higher than that observed in Groups 1 or 2. Russo et al. reported that the frequency of eGFR < 60 mL/min/1.73 m² in elderly patients with diabetes aged ≥ 75 years in Italy was 44.3% [7]. The results of this study were consistent with the findings of the above-mentioned report.

In contrast, Imai et al. examined the prevalence of CKD in the general Japanese population and reported that, in both men and women, eGFR decreased with age and, in men, the prevalence was 27.7% in those aged 70–79 years and 44.6% in those aged ≥ 80 years. In women, the prevalence was 31.1% in those aged 70–79 years and 46.1% in those aged ≥ 80 years [11]. In this study, the frequencies of CKD in those aged ≥ 75 years were 38.6% in men and 45.5% in women. Although the exact age category differed, the results of this study were roughly consistent with those reported by Imai et al [11]. Further studies on decreased eGFR in elderly patients with diabetes are required to confirm the contribution of aging and diabetes.

In the study on A classification, the frequency of A2 in Group 3 was 34.5%, which was higher than in the other two groups. Regarding A2, it was reported that 33.3% of patients aged ≥ 80 years [6] and 33.7% of patients aged ≥ 75 years [7] had microalbuminuria, and the effects of aging and diabetes on microalbuminuria should be considered. The results of this study were consistent with the above-mentioned reports it was considered that aging and diabetes influenced microalbuminuria in elderly patients with type 2 diabetes.

Subsequently, using the staging of CKD, the frequency of A classification in G3a + G3b + G4, corresponding to CKD, was examined. Overall, the frequency of A1 in Group 3 was lower compared to those in the other two groups but was higher in G3a + G3b + G4. Therefore, in G3a + G3b + G4, the frequencies of A1 and A2 in Group 3 were higher than those observed in the other two groups. Based on the above-mentioned findings, it was characteristic in elderly patients with type 2 diabetes that low eGFR (< 60 mL/min/1.73 m²) with normo- and microalbuminuria was frequently observed. This group accounted for 31.8% of patients with type 2 diabetes aged ≥ 75 years.

It has been reported that, in elderly patients with diabetes, the frequency of macroangiopathy and hypertension and the risk of cardiovascular disease are high [2, 7], but there has been no report on the examination of patients classified by renal function and proteinuria. In the clinical profiles of patients with low eGFR with normo- and microalbuminuria, there were more women, and the disease duration was longer. Moreover, 72.2% had hypertension, 47.2% had
Table 5  Clinical profiles of patients with A1 + A2 and A3 in G3a + G3b + G4 in each group

|                     | Group 1 | Group 2 | Group 3 |
|---------------------|---------|---------|---------|
| **Cases**           | A1 + A2 | A3      | A1 + A2 | A3       | A1 + A2 | A3       |
|                     | 26      | 18      | 62      | 33       | 72      | 23       |
| **Age (years)**     | 59.7 ± 5.5 | 55.0 ± 7.4 | 70.1 ± 2.8 | 69.6 ± 2.7 | 80.6 ± 4.4 | 81.8 ± 4.8 |
| **Males/females**   | 22/4    | 16/2    | 34/28   | 25/8     | 34/38   | 11/12    |
| **Disease duration (years)** | 10.4 ± 4.8<sup>a</sup> | 14.9 ± 5.9 | 12.7 ± 6.0 | 12.8 ± 5.7 | 15.2 ± 7.1<sup>b</sup> | 22.0 ± 8.4 |
| **BMI (kg/m²)**     | 25.8 ± 2.9 | 27.6 ± 4.6 | 24.6 ± 3.2 | 25.7 ± 4.6 | 23.5 ± 2.8 | 23.5 ± 3.5 |
| **eGFR (ml/minute/1.73 m²)** | 49.9 ± 8.6<sup>b</sup> | 37.3 ± 11.9 | 49.4 ± 7.6 | 42.1 ± 13.8 | 47.1 ± 9.0<sup>c</sup> | 37.7 ± 12.8 |
| **Urine albumin (mg/g Cr)** | 34.8 ± 39.3 | 1776.0 ± 1793.6<sup>c</sup> | 50.5 ± 66.1 | 465.5 ± 162.0<sup>d</sup> | 52.7 ± 69.4 | 705.9 ± 480.2<sup>e</sup> |
| **Hemoglobin A1c (%)** | 7.1 ± 1.2 | 7.6 ± 1.5 | 6.8 ± 0.7<sup>f</sup> | 7.3 ± 0.8 | 6.9 ± 0.8 | 7.2 ± 1.0 |
| **Hb (g/dl)**       | 13.8 ± 1.3 | 13.3 ± 2.1 | 13.5 ± 1.4 | 12.8 ± 1.5 | 12.6 ± 1.3 | 12.3 ± 1.7 |
| **RBC (x104)**      | 428.0 ± 73.3 | 433.1 ± 72.5 | 441.4 ± 45.1 | 417.8 ± 48.4 | 413.2 ± 43.1 | 398.5 ± 59.1 |
| **T-Ch (mg/dl)**    | 188.3 ± 28.7 | 175.6 ± 29.0 | 179.8 ± 25.4 | 173.5 ± 28.5 | 174.9 ± 28.5 | 175.8 ± 27.7 |
| **TG (mg/dl)**      | 180.6 ± 75.6 | 207.6 ± 194.7 | 153.1 ± 90.2 | 145.4 ± 60.6 | 134.7 ± 61.9 | 151.6 ± 84.8 |
| **HDL-C (mg/dl)**   | 48.2 ± 14.9 | 49.1 ± 14.8 | 50.1 ± 14.7 | 52.2 ± 18.9 | 50.6 ± 15.8 | 46.5 ± 16.6 |
| **LDL-C (mg/dl)**   | 104.0 ± 23.5 | 104.3 ± 44.5 | 99.2 ± 23.9 | 105.1 ± 26.4 | 97.4 ± 25.1 | 99.0 ± 22.6 |
| **Uric acid (mg/dl)** | 6.2 ± 1.4 | 6.3 ± 1.3 | 6.0 ± 1.3 | 5.8 ± 1.4 | 5.9 ± 1.2 | 6.0 ± 1.1 |
| **sBP (mmHg)**      | 124.8 ± 14.3<sup>b</sup> | 143.0 ± 17.7 | 129.4 ± 11.5<sup>f</sup> | 134.8 ± 10.9 | 128.7 ± 9.4 | 132.2 ± 12.5 |
| **dBP (mmHg)**      | 73.8 ± 7.8<sup>b</sup> | 83.1 ± 6.9 | 73.5 ± 6.0 | 74.5 ± 5.5 | 72.1 ± 5.7 | 72.4 ± 6.0 |
| **Retinopathy (yes/no)** | 3/23<sup>b</sup> | 18/0 | 21/41<sup>f</sup> | 28/5 | 14/58<sup>i</sup> | 20/3 |
| **Hypertension (yes/no)** | 15/11<sup>b</sup> | 17/1 | 41/21<sup>f</sup> | 33/0 | 52/20<sup>i</sup> | 20/3 |
| **ARB/ACE-I (yes/no)** | 11/15<sup>b</sup> | 14/4 | 31/31<sup>f</sup> | 24/9 | 31/41<sup>i</sup> | 15/8 |
| **CCB (yes/no)**    | 7/19<sup>b</sup> | 13/5 | 23/39<sup>f</sup> | 24/9 | 40/32<sup>i</sup> | 16/7 |
| **Dyslipidemia (yes/no)** | 16/10 | 9/9 | 35/27 | 20/13 | 34/38<sup>i</sup> | 15/8 |
| **Statin (yes/no)** | 9/17 | 6/12 | 29/33 | 17/16 | 34/38s | 15/8 |
| **Fibrate (yes/no)** | 6/20<sup>b</sup> | 1/17 | 2/60 | 2/31 | 4/68 | 0/23 |
| **CHD (yes/no)**    | 3/23 | 3/15 | 6/56<sup>g</sup> | 10/23 | 23/49 | 9/14 |
| **CVD (yes/no)**    | 2/24 | 3/15 | 9/53 | 6/27 | 16/56 | 6/17 |
| **PAD (yes/no)**    | 1/25<sup>e</sup> | 4/14 | 2/60<sup>f</sup> | 4/29 | 8/64 | 2/21 |
| **Therapy (D/O/I)** | 5/18/3<sup>f</sup> | 2/8/8 | 9/42/11<sup>g</sup> | 1/18/14 | 11/55/6<i>l</i> | 3/11/9 |

BMI body mass index, eGFR estimated glomerular filtration rate, CPG casual plasma glucose, HbA1c hemoglobin A1c, Hb hemoglobin, RBC red blood cell, T-Ch total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, sBP systolic blood pressure, dBP diastolic blood pressure, ARB angiotensin II receptor blocker, ACE-I angiotensin-converting-enzyme inhibitor, CCB calcium channel blocker, CHD coronary heart disease, CVD cerebrovascular disease, PAD peripheral artery disease, Therapy (D/O/I) therapy (diet/oral agents/insulin)

Group 1. A1 + A2 vs. A3

<sup>a</sup>p = 0.0027  
<sup>b</sup>p < 0.0001  
<sup>c</sup>n = 5  
<sup>d</sup>n = 13  
<sup>e</sup>p = 0.0242  
<sup>f</sup>p = 0.0155

Group 2. A1 + A2 vs. A3

<sup>g</sup>p < 0.0001  
<sup>h</sup>n = 7  
<sup>i</sup>n = 26  
<sup>j</sup>p = 0.0018  
<sup>k</sup>p = 0.0130  
<sup>l</sup>p = 0.0319
dyslipidemia, and 65.3% had macroangiopathy. Compared with patients with low eGFR with normo- and microalbuminuria in the other two groups, the frequency of retinopathy was lower than that of the 65–74-year age group, but the frequency of macroangiopathy was higher. In this group, macroangiopathy was more common than microangiopathy. The renal lesions in this group from the above clinical profiles are complex, which are likely related to aging kidneys, nephropathy with diabetes, nephrosclerosis with hypertension, and ischemic nephropathy with aortic arteriosclerosis due to dyslipidemia.

The frequency of patients with low eGFR with proteinuria in type 2 diabetes aged ≥ 75 years was 10.2%, and there was no difference compared to that in the 65–74-year age group. In clinical profiles of this group, there were more women, and the disease duration was longer. Moreover, 87.0% had retinopathy, 87.0% had hypertension, 65.2% had dyslipidemia, and 73.9% had macroangiopathy. In patients with low eGFR with proteinuria, there was no difference in frequency of retinopathy and macroangiopathy among the three groups, and age had no influence. It is considered that diabetic nephropathy caused the main lesion, and aging kidneys, hypertensive nephrosclerosis, and ischemic nephropathy are associated with it.

In all groups with low eGFR, the frequency of retinopathy was lower in patients with normo- and microalbuminuria compared to those in patients with proteinuria. In Groups 1 and 2, the frequency of macroangiopathy was lower in patients with normo- and microalbuminuria compared to those in patients with proteinuria. In Group 3, there was no difference in the frequency of macroangiopathy between patients with normo- and microalbuminuria and those with proteinuria. In patients aged ≥ 75 years with diabetes, the principle that the progression of microangiopathy and macroangiopathy is parallel, which was found in the other two groups, is not applicable.

This study had several limitations. This was a cross-sectional study in one center, and measurement of eGFR and U-Alb was performed only once. Moreover, the duration of diabetes was longer in patients in Group 3.

**Conclusion**

Using the CKD staging system, I reported the renal status in elderly type 2 diabetic patients and the frequency of macroangiopathy was associated with renal status. This report will be useful for the treatment of elderly patients with type 2 diabetes in the future.

**Acknowledgements**  The author would like to thank Enago (www.enago.jp) for the English language review.

**Compliance with ethical standards**

**Conflict of interest**  The author declares no competing interests.

**Ethical approval**  The present study was approved by the ethical review board of the Japan Medical Association (Approval no. 29-7-1). All procedures were performed in accordance with the ethical standards of the institutional and/or national research committees and the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

**Informed consent**  The author released the contents of this study, and informed consent was obtained by opt-out system.

**Open Access**  This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Ministry of Health, Labor and Welfare. The situation on diabetes. In: Heisei 28 Survey on National Health and Nutrition. Tokyo, Japan: Ministry of Health, Labor and Welfare; 2017. https://www.mhlw.go.jp/bunya/kenkou/eyou/dl/15-houkoku-08.pdf. Accessed 13 Mar 2018.
2. Ikeda Y, Yamashita H, Takamatsu K, Hashimoto K. Clinical significance of microalbuminuria in elderly diabetic patients. Jpn J Geriat. 1994;31:616–20.
3. Sheen YJ, Sheu WHH. Risks of rapid decline renal function in patients with type 2 diabetes. World J Diabetes. 2014;5:835–46.
4. Kim KS, Park SW, Cho YW, Kim SK. Higher prevalence and progression rate of chronic kidney disease in elderly patients with type 2 diabetes mellitus. Diabetes Metab J. 2018;42:224–32.
5. Martínez Candelá J, Sangróis González J, García Soidán PJ, Millaruelo Trillo JM, Díez Espino J, Bordonaba Bosque D, et al. Chronic renal disease in Spain: prevalence and related factors in persons with diabetes mellitus older than 64 years. Nefrologia. 2018;38:401–13.
6. Wasen E, Isoaho R, Mattila K, Vahlberg T, Kivela SL, Irjala K. Renal impairment associated with diabetes in the elderly. Diabetes Care. 27:2648–53.
7. Russo GT, De Cosmo S, Viazzi F, Mirijello A, Ceriello A, Guida P, et al. Diabetic kidney disease in the elderly: prevalence and clinical correlates. BMC Geriatr. 2018;18:38.
8. CKD Treatment Guide 2012. CKD definition, diagnosis, severity classification. In: Edited by Japan Society of Nephrology. Tokyo: CKD Treatment Guide 2012; 2012. p. 3.
9. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. The Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Diabetol Int. 2010;1:2–20.
10. Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, et al. Prevalence of chronic kidney diseases (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol. 2007;11:156–63.
11. Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2009;13:621–30.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.